title: D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
abstract: The striatum, which is the major component of the basal ganglia in the brain, is regulated in part by dopaminergic input from the substantia nigra. Severe movement disorders result from the loss of striatal dopamine in patients with Parkinson's disease. Rats with lesions of the nigrostriatal dopamine pathway caused by 6-hydroxydopamine (6-OHDA) serve as a model for Parkinson's disease and show alterations in gene expression in the two major output systems of the striatum to the globus pallidus and substantia nigra. Striatopallidal neurons show a 6-OHDA-induced elevation in their specific expression of messenger RNAs (mRNAs) encoding the D2 dopamine receptor and enkephalin, which is reversed by subsequent continuous treatment with the D2 agonist quinpirole. Conversely, striatonigral neurons show a 6-OHDA-induced reduction in their specific expression of mRNAs encoding the D1 dopamine receptor and substance P, which is reversed by subsequent daily injections of the D1 agonist SKF-38393. This treatment also increases dynorphin mRNA in striatonigral neurons. Thus, the differential effects of dopamine on striatonigral and striatopallidal neurons are mediated by their specific expression of D1 and D2 dopamine receptor subtypes, respectively.
authors: Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, MD 20892.
authors: C R
authors: CR
authors: Gerfen
authors: T M
authors: TM
authors: Engber
authors: L C
authors: LC
authors: Mahan
authors: Z
authors: Z
authors: Susel
authors: T N
authors: TN
authors: Chase
authors: F J
authors: FJ
authors: Monsma
authors: D R
authors: DR
authors: Sibley
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000818:Animals; D002540:Cerebral Cortex / Q000502:physiology; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004873:Ergolines / Q000494:pharmacology; D005786:Gene Expression Regulation; D005917:Globus Pallidus / Q000187:drug effects / Q000378:metabolism*; D006892:Hydroxydopamines / Q000494:pharmacology; D008959:Models, Neurological; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D015345:Oligonucleotide Probes; D016627:Oxidopamine; D019257:Quinpirole; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics*; D051381:Rats; D011954:Receptors, Dopamine / Q000235:genetics*; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism*; D013788:Thalamus / Q000502:physiology
chemical_list: D004873:Ergolines; D006892:Hydroxydopamines; D015345:Oligonucleotide Probes; D012333:RNA, Messenger; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D019257:Quinpirole; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D016627:Oxidopamine